ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00721435
Recruitment Status : Completed
First Posted : July 24, 2008
Last Update Posted : January 24, 2017
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Paul L. Carson Ph.D, University of Michigan

Brief Summary:
The study will evaluate and refine a breast screening and diagnosis device.

Condition or disease Intervention/treatment Phase
Breast Cancer Mass Cystic Benign Mass Procedure: 3D Tomosynthesis and ultrasound imaging Not Applicable

Detailed Description:
The device produces 3-D mammograms and ultrasound pictures of the breast at the same time and in the same position. This should help make sure that any area on a mammogram can be easily found in the ultrasound when using the new device. The 3-D mammograms should provide better visualization of the suspected lesion and improve diagnostic accuracy.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 183 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Study Start Date : April 2002
Actual Primary Completion Date : December 2014
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound X-Rays
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 3D Tomosynthesis & 3D Ultrasound for breast masses
Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
Procedure: 3D Tomosynthesis and ultrasound imaging
3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue
Experimental: 3D Tomosynthesis/ 3D Ultrasound for healthy subjects
Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
Procedure: 3D Tomosynthesis and ultrasound imaging
3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue



Primary Outcome Measures :
  1. To have a device that produces 3D/ultrasound imaging of the breast at the same time and in the same position. [ Time Frame: To be determined later. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • To participate in this research study you must be a female over the age of 25
  • Have had a normal mammogram or are scheduled for a breast biopsy
  • Have cysts or have been recommended to have a 6 month follow up mammogram after your biopsy.

Exclusion Criteria:

  • Male
  • Under the age of 25
  • Documented breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00721435


Locations
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109-0554
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Investigators
Principal Investigator: Paul L Carson, PHD University of Michigan

Responsible Party: Paul L. Carson Ph.D, Principal Investigator, University of Michigan
ClinicalTrials.gov Identifier: NCT00721435     History of Changes
Other Study ID Numbers: HUM00045519 (2002-0584)
R01CA091713 ( U.S. NIH Grant/Contract )
First Posted: July 24, 2008    Key Record Dates
Last Update Posted: January 24, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No